JP5602230B2 - スフィンゴシン−１−リン酸受容体アゴニスト - Google Patents

スフィンゴシン−１−リン酸受容体アゴニスト Download PDF

Info

Publication number
JP5602230B2
JP5602230B2 JP2012523967A JP2012523967A JP5602230B2 JP 5602230 B2 JP5602230 B2 JP 5602230B2 JP 2012523967 A JP2012523967 A JP 2012523967A JP 2012523967 A JP2012523967 A JP 2012523967A JP 5602230 B2 JP5602230 B2 JP 5602230B2
Authority
JP
Japan
Prior art keywords
phenyl
oxadiazol
trifluoromethyl
ethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012523967A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501729A5 (cg-RX-API-DMAC7.html
JP2013501729A (ja
Inventor
ジョン・エル・ギルモア
ジェイムズ・イー・シェペック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2013501729A publication Critical patent/JP2013501729A/ja
Publication of JP2013501729A5 publication Critical patent/JP2013501729A5/ja
Application granted granted Critical
Publication of JP5602230B2 publication Critical patent/JP5602230B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2012523967A 2009-08-07 2010-08-06 スフィンゴシン−１−リン酸受容体アゴニスト Expired - Fee Related JP5602230B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23205409P 2009-08-07 2009-08-07
US61/232,054 2009-08-07
PCT/US2010/044627 WO2011017578A1 (en) 2009-08-07 2010-08-06 Sphingosine-1-phosphate receptor agonists

Publications (3)

Publication Number Publication Date
JP2013501729A JP2013501729A (ja) 2013-01-17
JP2013501729A5 JP2013501729A5 (cg-RX-API-DMAC7.html) 2013-08-08
JP5602230B2 true JP5602230B2 (ja) 2014-10-08

Family

ID=43029859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012523967A Expired - Fee Related JP5602230B2 (ja) 2009-08-07 2010-08-06 スフィンゴシン−１−リン酸受容体アゴニスト

Country Status (19)

Country Link
US (1) US8399451B2 (cg-RX-API-DMAC7.html)
EP (1) EP2462139B1 (cg-RX-API-DMAC7.html)
JP (1) JP5602230B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120108963A (cg-RX-API-DMAC7.html)
CN (1) CN102548989A (cg-RX-API-DMAC7.html)
AR (1) AR077819A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010279354A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012002824A2 (cg-RX-API-DMAC7.html)
CA (1) CA2770194A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012000326A1 (cg-RX-API-DMAC7.html)
CO (1) CO6430439A2 (cg-RX-API-DMAC7.html)
EA (1) EA201270266A1 (cg-RX-API-DMAC7.html)
ES (1) ES2533095T3 (cg-RX-API-DMAC7.html)
MX (1) MX2012001160A (cg-RX-API-DMAC7.html)
PE (1) PE20120732A1 (cg-RX-API-DMAC7.html)
SG (1) SG177691A1 (cg-RX-API-DMAC7.html)
TW (1) TW201109323A (cg-RX-API-DMAC7.html)
WO (1) WO2011017578A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201200641B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007310897A1 (en) * 2006-10-25 2008-05-02 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
EP2560969B1 (en) * 2010-04-23 2015-08-12 Bristol-Myers Squibb Company 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists
EP2595969B1 (en) 2010-07-20 2015-04-22 Bristol-Myers Squibb Company Substituted 3-phenyl-1,2,4-oxadiazole compounds
ES2548258T3 (es) 2010-09-24 2015-10-15 Bristol-Myers Squibb Company Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1
US8629282B2 (en) 2010-11-03 2014-01-14 Bristol-Myers Squibb Company Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases
UY35338A (es) 2013-02-21 2014-08-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen
UY36274A (es) 2014-08-20 2016-02-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g
UY38367A (es) * 2018-09-13 2020-04-30 Syngenta Participations Ag Compuestos de azol-amida pesticidamente activos
CN114181276A (zh) * 2021-12-17 2022-03-15 安徽大学 硫酯肽合成方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
JPS6480026A (en) 1987-09-21 1989-03-24 Mitsubishi Electric Corp Resist coater
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
TW432061B (en) 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
US6069143A (en) * 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
AU4064597A (en) 1996-08-16 1998-03-06 Du Pont Pharmaceuticals Company Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
AU2003216054B2 (en) * 2002-01-18 2007-01-04 Merck & Co., Inc. Selective S1P1/Edg1 receptor agonists
DE60329073D1 (de) 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
JP4709488B2 (ja) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
US7309721B2 (en) * 2002-03-01 2007-12-18 Merck + Co., Inc. Aminoalkylphosphonates and related compounds as Edg receptor agonists
CA2483164C (en) * 2002-04-23 2011-06-07 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
JP2005533058A (ja) 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
AU2003279915A1 (en) 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
WO2004058149A2 (en) 2002-12-20 2004-07-15 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles
EP1594508B1 (en) 2003-02-11 2012-08-08 Irm Llc Novel bicyclic compounds and compositions
CA2524867A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
BRPI0410746A (pt) 2003-05-19 2006-06-27 Irm Llc compostos e composições imunossupressoras
AU2004251146A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
WO2004103309A2 (en) 2003-05-19 2004-12-02 Irm Llc Immunosuppressant compounds and compositions
JP2007528872A (ja) * 2003-10-01 2007-10-18 メルク　エンド　カムパニー　インコーポレーテッド Ｓ１ｐ受容体アゴニストとしての３，５−アリール置換、ヘテロアリール置換またはシクロアルキル置換された１，２，４−オキサジアゾール化合物
AU2004299456B2 (en) 2003-12-17 2010-10-07 Merck Sharp & Dohme Corp. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
WO2006047195A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
JP2008530135A (ja) 2005-02-14 2008-08-07 ユニバーシティ オブ バージニア パテント ファンデーション アミノ基およびフェニル基で置換されたシクロアルカンならびに５員の複素環を含むスフィンゴシン＝１−リン酸アゴニスト
AU2006226018B2 (en) 2005-03-23 2012-07-12 Idorsia Pharmaceuticals Ltd Hydrogenated benzo (C) thiophene derivatives as immunomodulators
DK1863474T3 (da) 2005-03-23 2009-02-09 Actelion Pharmaceuticals Ltd Hidtil ukendte thiophenderivater som sphingosin-1-phosphat-1-receptoragonister
RU2382781C2 (ru) 2005-04-22 2010-02-27 Дайити Санкио Компани, Лимитед Гетероциклическое соединение
KR20080014009A (ko) 2005-06-08 2008-02-13 노파르티스 아게 폴리시클릭 옥사디아졸 또는 이속사졸, 및 이들의 ｓ１ｐ수용체 리간드로서의 용도
BRPI0611631A2 (pt) 2005-06-24 2010-09-21 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
AU2006283175A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
TW200800911A (en) 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
JP2009520688A (ja) * 2005-11-23 2009-05-28 エピックス デラウェア， インコーポレイテッド Ｓ１ｐ受容体調節化合物およびそれらの使用
TWI404706B (zh) 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
TW200806611A (en) 2006-02-09 2008-02-01 Daiichi Seiyaku Co Novel amidopropionic acid derivatives and medicine containing the same
TW200806633A (en) 2006-03-21 2008-02-01 Epix Pharm Inc S1P receptor modulating compounds and use thereof
WO2007116866A1 (ja) 2006-04-03 2007-10-18 Astellas Pharma Inc. ヘテロ化合物
US20100016260A1 (en) 2006-08-01 2010-01-21 Praecis Pharmaceuticals Incorporated Agonists of sphingosine-1 phosphate receptor (slp)
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
CN101511827B (zh) 2006-09-07 2012-02-01 埃科特莱茵药品有限公司 作为免疫调制剂的吡啶-4-基衍生物
JP2010504286A (ja) 2006-09-07 2010-02-12 アラーガン インコーポレイテッド スフィンゴシン−１−リン酸（ｓ１ｐ）受容体アゴニスト及び／又はアンタゴニスト生物活性を有するヘテロ芳香族化合物
TWI408139B (zh) 2006-09-07 2013-09-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
BRPI0716633A2 (pt) * 2006-09-08 2013-09-24 Actelion Pharmaceuticals Ltd compostos derivados de piridin-3-ila, composiÇço farmacÊutica e uso de um composto como agente imunomodulador
CA2662091A1 (en) 2006-09-08 2008-03-13 Novartis Ag N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions
WO2008035239A1 (en) 2006-09-21 2008-03-27 Actelion Pharmaceuticals Ltd Phenyl derivatives and their use as immunomodulators
AU2007302262A1 (en) 2006-09-29 2008-04-03 Novartis Ag Oxadiazole derivatives with anti-inflammatory and immunosuppressive properties
CA2669102A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
JP2010513283A (ja) 2006-12-15 2010-04-30 アボット・ラボラトリーズ 新規なオキサジアゾール化合物
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
RU2009128062A (ru) 2006-12-21 2011-01-27 Эбботт Лэборетриз (Us) Соединения агонисты и антагонисты рецептора сфингозин-1-фосфата
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
NZ580454A (en) 2007-03-16 2011-05-27 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
EP2137181B1 (en) * 2007-04-19 2011-03-02 Glaxo Group Limited Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
US8202865B2 (en) 2007-10-04 2012-06-19 Merck Serono Sa Oxadiazole derivatives
BRPI0817597A2 (pt) 2007-10-04 2015-04-07 Merck Serono Sa Compostos de diarila de oxadiazol, processo para sua preparação, composições farmacêuticas e kit compreendendo os mesmos, bem como seus usos
CN101970430B (zh) 2007-11-01 2013-05-08 埃科特莱茵药品有限公司 嘧啶衍生物
MX2010007026A (es) 2007-12-21 2010-10-05 Merck Serono Sa Derivados de triazoloxadiazoles.
PT2291080E (pt) 2008-05-14 2015-10-30 Scripps Research Inst Novos modelamodeladores dos recetores da esfingosina fosfato
WO2010041655A1 (ja) 2008-10-06 2010-04-15 昭和電工株式会社 触媒およびその製造方法ならびにその用途
US20100160369A1 (en) * 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using
EP2354134B1 (en) 2008-12-05 2016-02-24 Astellas Pharma Inc. 2h-chromene derivatives as stimulators of sphingosine 1-phosphate receptor
JP5855942B2 (ja) 2008-12-18 2016-02-09 メルク セローノ ソシエテ アノニム 多発性硬化症の治療に有用なオキサジアゾール縮合複素環式誘導体
WO2010072712A1 (en) 2008-12-23 2010-07-01 Novartis Ag Biaryl benzylamine derivatives
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
CN102361868A (zh) 2009-01-23 2012-02-22 百时美施贵宝公司 作为1-磷酸-鞘氨醇激动剂的吡唑-1，2，4-噁二唑衍生物
EP2382212B1 (en) 2009-01-23 2014-07-16 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
WO2010085582A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
JP5669363B2 (ja) 2009-03-31 2015-02-12 昭和電工株式会社 樹脂組成物及びこれで処理された紙又は繊維加工品
WO2010113528A1 (en) 2009-04-03 2010-10-07 Panasonic Corporation Mobile communication method, mobile communication system, and corresponding apparatus

Also Published As

Publication number Publication date
ES2533095T3 (es) 2015-04-07
PE20120732A1 (es) 2012-06-20
KR20120108963A (ko) 2012-10-05
CA2770194A1 (en) 2011-02-10
EP2462139B1 (en) 2015-01-14
JP2013501729A (ja) 2013-01-17
WO2011017578A1 (en) 2011-02-10
EP2462139A1 (en) 2012-06-13
AR077819A1 (es) 2011-09-28
US20110190255A1 (en) 2011-08-04
ZA201200641B (en) 2013-06-26
AU2010279354A1 (en) 2012-02-09
MX2012001160A (es) 2012-02-13
US8399451B2 (en) 2013-03-19
CO6430439A2 (es) 2012-04-30
CL2012000326A1 (es) 2012-10-19
SG177691A1 (en) 2012-02-28
CN102548989A (zh) 2012-07-04
EA201270266A1 (ru) 2012-07-30
TW201109323A (en) 2011-03-16
BR112012002824A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
JP5728487B2 (ja) 三環式ヘテロ環化合物
JP5602230B2 (ja) スフィンゴシン−１−リン酸受容体アゴニスト
EP2382212B1 (en) Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
US8389509B2 (en) Substituted pyrazole compounds
EP2389377B1 (en) Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
TW202045498A (zh) 作為法尼醇x受體調節劑之經取代雙環化合物
JP2013544811A (ja) 自己免疫疾患および血管疾患の治療用のｓ１ｐ１アゴニストとしての複素環式化合物
JP5735634B2 (ja) スフィンゴシン−１−リン酸受容体１アゴニストとしての４−（５−イソオキサゾリルまたは５−ピラゾリル−１，２，４−オキサジアゾール−３−イル）−マンデル酸アミド化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130619

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140722

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140819

R150 Certificate of patent or registration of utility model

Ref document number: 5602230

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees